BiotechTube
InnSight Technology

InnSight Technology

Seattle, United States· Est.
innsightech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

InnSight Technology is pioneering point-of-care diagnostics through its OcuCheck biosensor, a device that analyzes tear fluid for proteins linked to conditions like dry eye disease and diabetes. The platform aims to provide rapid, quantitative results to improve diagnostic accuracy and patient management in optometry and broader healthcare settings. As a private, pre-revenue company, InnSight is seeking investment to advance its technology through development and towards commercialization.

OphthalmologyEndocrinology

Technology Platform

Proprietary electrochemical biosensor platform for multiplex, quantitative analysis of protein biomarkers in tear fluid.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The large and growing markets for dry eye disease diagnostics and diabetes management present a significant dual opportunity.
Successfully commercializing a non-invasive, multiplex tear test could establish a new standard of care in optometry and create a novel channel for systemic disease screening.

Risk Factors

Key risks include the technical challenge of validating tear biomarkers for systemic conditions, navigating complex regulatory pathways for a novel diagnostic device, and achieving clinical adoption and reimbursement in a competitive market.

Competitive Landscape

In dry eye diagnostics, InnSight faces competition from established single-analyte tests like Quidel's InflammaDry (MMP-9). In diabetes, it indirectly competes with the entrenched blood glucose monitoring and CGM industry. Its primary advantage is the proposed multiplex, quantitative tear fluid platform, a first-mover approach in this specific niche.

More companies in Diagnostics & Precision Medicine →More companies in United States →